View in EDS

Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.

Saved in:
Bibliographic Details
Title: Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.
Authors: Hung CL; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Hsu WN; Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan., Wang TC; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan., Chen WR; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Chen YT; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Kuo ZK; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Hu TL; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Lin YC; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Yeh HH; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan., Lin HC; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan., Yu CJ; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Department of Cell and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan; Molecular Medicine Research Center, Chang Gung University, Taoyuan 33305, Taiwan; Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan., Fu CW; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Liu HH; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Hsu HC; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan., Lin PH; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan., Pang ST; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan., Lai CH; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Department of Microbiology and Immunology, Chang Gung University, Taoyuan 33302, Taiwan., Wang LY; Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan. Electronic address: lywang@mail.cgu.edu.tw.
Source: Neoplasia (New York, N.Y.) [Neoplasia] 2026 Jan; Vol. 71, pp. 101253. Date of Electronic Publication: 2025 Nov 13.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41237749
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hung+CL%22">Hung CL</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Hsu+WN%22">Hsu WN</searchLink>; Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wang+TC%22">Wang TC</searchLink>; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+WR%22">Chen WR</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+YT%22">Chen YT</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Kuo+ZK%22">Kuo ZK</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Hu+TL%22">Hu TL</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lin+YC%22">Lin YC</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yeh+HH%22">Yeh HH</searchLink>; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lin+HC%22">Lin HC</searchLink>; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yu+CJ%22">Yu CJ</searchLink>; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Department of Cell and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan; Molecular Medicine Research Center, Chang Gung University, Taoyuan 33305, Taiwan; Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan.<br /><searchLink fieldCode="AU" term="%22Fu+CW%22">Fu CW</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Liu+HH%22">Liu HH</searchLink>; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan.<br /><searchLink fieldCode="AU" term="%22Hsu+HC%22">Hsu HC</searchLink>; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lin+PH%22">Lin PH</searchLink>; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan.<br /><searchLink fieldCode="AU" term="%22Pang+ST%22">Pang ST</searchLink>; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lai+CH%22">Lai CH</searchLink>; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Department of Microbiology and Immunology, Chang Gung University, Taoyuan 33302, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wang+LY%22">Wang LY</searchLink>; Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan. Electronic address: lywang@mail.cgu.edu.tw.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100886622%22">Neoplasia (New York, N.Y.)</searchLink> [Neoplasia] 2026 Jan; Vol. 71, pp. 101253. <i>Date of Electronic Publication: </i>2025 Nov 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100886622 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5586 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214765586%22">14765586 </searchLink><i>NLM ISO Abbreviation: </i>Neoplasia <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41237749
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.neo.2025.101253
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 101253
    Titles:
      – TitleFull: Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hung CL
      – PersonEntity:
          Name:
            NameFull: Hsu WN
      – PersonEntity:
          Name:
            NameFull: Wang TC
      – PersonEntity:
          Name:
            NameFull: Chen WR
      – PersonEntity:
          Name:
            NameFull: Chen YT
      – PersonEntity:
          Name:
            NameFull: Kuo ZK
      – PersonEntity:
          Name:
            NameFull: Hu TL
      – PersonEntity:
          Name:
            NameFull: Lin YC
      – PersonEntity:
          Name:
            NameFull: Yeh HH
      – PersonEntity:
          Name:
            NameFull: Lin HC
      – PersonEntity:
          Name:
            NameFull: Yu CJ
      – PersonEntity:
          Name:
            NameFull: Fu CW
      – PersonEntity:
          Name:
            NameFull: Liu HH
      – PersonEntity:
          Name:
            NameFull: Hsu HC
      – PersonEntity:
          Name:
            NameFull: Lin PH
      – PersonEntity:
          Name:
            NameFull: Pang ST
      – PersonEntity:
          Name:
            NameFull: Lai CH
      – PersonEntity:
          Name:
            NameFull: Wang LY
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2026 Jan
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1476-5586
          Numbering:
            – Type: volume
              Value: 71
          Titles:
            – TitleFull: Neoplasia (New York, N.Y.)
              Type: main
ResultId 1